A Single-centre Study on Abnormal Antinuclear Antibodies in Children Caused by Intravenous Infusion of Gamma Globulin

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Aug 2

PMID 39091491

Authors

Li Xu

Juan Zhou

Yu Zhang

Yating Wang

Xin Yan

Li Wang

Xuemei Tang

Chong Luo

Affiliations

Soon will be listed here.

Abstract

Objective: To clarify the impact of intravenous infusion of gamma globulin (IVIg) on antinuclear antibodies (ANAs) in children.

Methods: A retrospective analysis was performed on the data of children with nonspecific autoantibody-related diseases whose antinuclear antibody (ANA) and autoantibody profiles were detected in our hospital from January to March 2022. A total of 108 patients with a clear history of IVIg infusion within 28 days composed the IVIg group, and 1201 patients without a history of IVIg infusion composed the non-IVIg group.

Results: All patients in the IVIg group had either positive ANAs or positive autoantibodies. Anti-SSA, anti-Ro52 and anti-AMA Mi2 were the top three autoantibodies in the IVIg group. The proportions of patients who were positive for either of these three autoantibodies in the IVIg group were significantly greater than those in the non-IVIg group (all P<0.5). Spearman correlation analysis revealed that the signal intensities of anti-SSA and anti-Ro52 were negatively correlated with the number of days of ANA detection after IVIg infusion (P<0.05). Multiple logistic analyses revealed that a greater total dosage of IVIg, greater IVIg per kilogram of body weight, and fewer ANA detection days after IVIg infusion were independent risk factors for positive anti-SSA and anti-Ro52 results.

Conclusions: It is recommended that if rheumatic diseases are suspected, ANA detection should be carried out beforeIVIg infusion. But for patients who are positive for at least one of these three autoantibodies after IVIg infusion, doctors should first consider adoptive antibodies.

References

Shome M, Chung Y, Chavan R, Park J, Qiu J, LaBaer J . Serum autoantibodyome reveals that healthy individuals share common autoantibodies. Cell Rep. 2022; 39(9):110873. PMC: 9221390. DOI: 10.1016/j.celrep.2022.110873. View

Ergenc I, Gozaydinoglu B, Keklikkiran C, Yilmaz Y . The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients. Hepatol Forum. 2023; 4(2):69-73. PMC: 10209978. DOI: 10.14744/hf.2023.2023.0016. View

Grygiel-Gorniak B, Rogacka N, Puszczewicz M . Antinuclear antibodies in healthy people and non-rheumatic diseases - diagnostic and clinical implications. Reumatologia. 2018; 56(4):243-248. PMC: 6142026. DOI: 10.5114/reum.2018.77976. View

Pisetsky D, Bossuyt X, Meroni P . ANA as an entry criterion for the classification of SLE. Autoimmun Rev. 2019; 18(12):102400. DOI: 10.1016/j.autrev.2019.102400. View

Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff I, Miller F, Rider L . Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis. 2019; 78(7):988-995. PMC: 7570952. DOI: 10.1136/annrheumdis-2018-215004. View

Huang H, Chen J, Dang H, Liu C, Huo J, Fu Y . Effect of intravenous immunoglobulin on the outcome of children with septic shock in a PICU: a retrospective cohort study. Eur J Pediatr. 2023; 182(12):5315-5323. DOI: 10.1007/s00431-023-05224-5. View

Emara M, Mohsen E, Shawky R, El-Domany R . Assessment of the Prevalence of Non-Organ-Specific Autoantibodies in Egyptian Patients with HCV. Immunol Invest. 2019; 49(6):676-686. DOI: 10.1080/08820139.2019.1699108. View

Im J, Chung M, Park Y, Kwon H, Baek J, Lee S . Antinuclear antibodies in infectious diseases. Infect Dis (Lond). 2019; 52(3):177-185. DOI: 10.1080/23744235.2019.1690676. View

Gruter T, Ott A, Meyer W, Jarius S, Kinner M, Motte J . Effects of IVIg treatment on autoantibody testing in neurological patients: marked reduction in sensitivity but reliable specificity. J Neurol. 2019; 267(3):715-720. DOI: 10.1007/s00415-019-09614-4. View

10.

Samadli S, Liu F, Mammadov G, Wang J, Liu H, Wu Y . The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease. Pediatr Rheumatol Online J. 2019; 17(1):53. PMC: 6668082. DOI: 10.1186/s12969-019-0352-3. View

11.

Shiboski C, Shiboski S, Seror R, Criswell L, Labetoulle M, Lietman T . 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol. 2016; 69(1):35-45. PMC: 5650478. DOI: 10.1002/art.39859. View

12.

Pisetsky D . Annals of the Rheumatic Diseases collection on autoantibodies in the rheumatic diseases: new insights into pathogenesis and the development of novel biomarkers. Ann Rheum Dis. 2023; 82(10):1243-1247. PMC: 11149592. DOI: 10.1136/ard-2023-224692. View

13.

Turan Farasat V, Ecemis T, Dogan Y, Sener A, Ece G, Erbay Dundar P . A Multicenter Analysis of Subjectivity of Indirect Immunofluorescence Test in Antinuclear Antibody Screening. Arch Rheumatol. 2019; 34(3):326-333. PMC: 6768788. DOI: 10.5606/ArchRheumatol.2019.7310. View

14.

Xing X, Li A, Li C . Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis. Respir Med. 2020; 172:106134. DOI: 10.1016/j.rmed.2020.106134. View

15.

Hou Y, Wang L, Luo C, Tang W, Dai R, An Y . Clinical characteristics of early-onset paediatric systemic lupus erythematosus in a single centre in China. Rheumatology (Oxford). 2023; 62(10):3373-3381. DOI: 10.1093/rheumatology/kead086. View

16.

Hamberg V, Sohrabian A, Volkmann E, Wildt M, Lofdahl A, Wuttge D . Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study. Arthritis Res Ther. 2023; 25(1):162. PMC: 10476305. DOI: 10.1186/s13075-023-03141-4. View

17.

Chen Y, Hu C, Peng L, Wang C, Zhao Y, Zhang W . Current state of technologies and recognition of anti-SSA/Ro antibodies in China: A multi-center study. J Clin Lab Anal. 2021; 35(12):e24045. PMC: 8649342. DOI: 10.1002/jcla.24045. View

18.

Lu X, Peng Q, Wang G . The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome. Curr Opin Rheumatol. 2019; 31(6):643-649. DOI: 10.1097/BOR.0000000000000641. View

19.

Dias B, Aguiar A, Iracema Morais C, Nery F . Correlation between individual autoantibodies and clinical features in primary biliary cholangitis: results of a retrospective longitudinal study. Eur J Gastroenterol Hepatol. 2023; 35(6):682-689. DOI: 10.1097/MEG.0000000000002565. View

20.

van der Molen R, Hamann D, Jacobs J, van der Meer A, De Jong J, Kramer C . Anti-SSA antibodies are present in immunoglobulin preparations. Transfusion. 2014; 55(4):832-7. DOI: 10.1111/trf.12922. View